How to Buy Marinus Pharmaceuticals Stock
Marinus Pharmaceuticals Inc
Marinus Pharmaceuticals, Inc. , a pharmaceutical company, focuses on development and commercialization of products for patients suffering from rare genetic epilepsies and other seizure disorders.
Marinus Pharmaceuticals stock last closed at $1.51, up 4.14% from the previous day, and has decreased 83.22% in one year. It has underperformed other stocks in the Biotechnology industry by 0.65 percentage points. Marinus Pharmaceuticals stock is currently +36.04% from its 52-week low of $1.11, and -86.59% from its 52-week high of $11.26.
At the moment, there are 54.64M MRNS shares outstanding. The market capitalization of MRNS is $82.51M. In the past 24 hours, 1.6M MRNS shares were traded.
How to Buy Marinus Pharmaceuticals Stock
Wondering how to invest in Marinus Pharmaceuticals stock? Here's how.
- Figure out where to buy Marinus Pharmaceuticals stock: You need to choose a stock brokerage, but don't worry - we've tried dozens of stock brokerages and apps to help you choose where to buy Marinus Pharmaceuticals stock.
- Sign up for your brokerage account: Sign up for 0% commission trading with the highest-rated brokerage we've identified.
- Put funds into your brokerage account: Select your method of payment and add your information.
- Evaluate Marinus Pharmaceuticals stock: The Marinus Pharmaceuticals ticker symbol is MRNS. Is Marinus Pharmaceuticals stock a good investment? Should you buy shares of MRNS? How do MRNS's underlying business fundamentals look? Do top analysts think Marinus Pharmaceuticals is a good buy? Why has MRNS's stock price moved recently? (Hint: Our stock analysis website can help you understand if MRNS is a good stock to buy).
- Execute your MRNS trade: Decide if you will purchase MRNS shares at the current market price or use a limit order to purchase MRNS stock at a particular price.
- Keep an eye on your MRNS investment: Create a watchlist to the latest updates on your investment in Marinus Pharmaceuticals stock.
Step 1: Figure out where to buy Marinus Pharmaceuticals stock
You will need a brokerage account to access the NASDAQ market and buy MRNS stock.
Our recommended brokerage: eToro
Based on our analysis, eToro is the best stock brokerage. eToro gives you:
- Invest in stocks with 0% commissions: Invest without commissions.
- Buy fractional shares: Even if you don't have the money to buy a full share, you can still invest in the stock.
- Access to world financial markets: From Tech to Financial Services, New York to London — you can fill your portfolio with stocks from the globe's top exchanges.
- Social investing: eToro boasts a community with more than 20 million users around the world. Talk to, learn from, and copy the crypto trades of top investors.
- Security: eToro is a regulated and licensed brokerage platform.
- Buy other financial assets: Such as ETFs and cryptos.
Get $10 towards your stock purchase by opening an account with eToro today.
Open eToro AccountStep 2: Sign up for your brokerage account
Now that you've selected the best brokerage, it's time to fill out some personal info so you are able to buy MRNS today.
How to Create a New Brokerage Account on eToro
- Click here to get started.eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk.
- Enter your personal data to create a new brokerage account.
- Send your data by hitting the "Create Account" button. Get started with eToro today
Step 3: Put funds into your brokerage account
Now that you've filled out your info on a mobile trading app, your next step is to transfer the money for your investment:
Check out the tutorial below if you need help depositing funds into your brokerage account.
Step 4: Evaluate Marinus Pharmaceuticals stock
Once you have decided on the best place to buy Marinus Pharmaceuticals stock, it's important to research their stock prior to investing, so you can comprehend the risk as well as the opportunity.
Marinus Pharmaceuticals Metrics
Marinus Pharmaceuticals Zen Score
WallStreetZen was designed to help part-time investors perform more accurate fundamental analysis quickly.
You can see all of the due diligence checks on MRNS's stock page.
Is MRNS stock properly valued?
You can use a variety of different financial metrics, analyses, models, and charts to gauge MRNS's intrinsic value.
Using relative valuations ratios:
- MRNS may be undervalued based on its P/B ratio of 4.92x, relative to Biotechnology industry P/B ratio of 6.01x
You can do more valuation analysis on MRNS's stock here.
MRNS Financial Health
Positive Health Checks:
- There are more short-term assets than long-term liabilities on the MRNS balance sheet.
- There are more short-term assets than short-term liabilities on the MRNS balance sheet.
- MRNS has cash burn of 118111000. It has sufficient cash and short-term investments to cover this for at least one year.
Negative Health Checks:
- MRNS has $150.29M in cash and short term investments. This is not sufficient to cover its annual cash burn of $118.11M.
- Total MRNS debt is higher than 5 years ago, relative to shareholder equity.
- MRNS profit margin has gone down from -77.8% to -456.3% in the past year.
- MRNS has a relatively high debt to equity ratio of 9.19.
Is it a good time to buy Marinus Pharmaceuticals stock, according to Wall Street analysts?
Out of 6 Equities analysts who track MRNS, the consensus analyst rating on MRNS is a Buy
It's important to note that analyst ratings are not recommendations, nor are they investment advice.
Most Recent MRNS Analyst Ratings
Jay Olson, a top 2% analyst from Oppenheimer maintains MRNS with a hold rating and maintains their MRNS price target from $9.00 to $9.00, on Mar 7, 2024.
You can dive deeper into what analysts are forecasting on the Marinus Pharmaceuticals stock forecast page.
MRNS Trading Indicators
MRNS Performance Numbers
Last year, MRNS revenue was $30.99M. During the last three year, MRNS's revenue has grown by 257.32% per year. This was faster than the Biotechnology industry average of 29.63%.
You can research MRNS's earnings and revenue performance here.
Who is buying/selling MRNS?
In the past year, insiders at MRNS have bought more shares than they have sold.
Scott Braunstein, CHAIRMAN AND CEO of MRNS, was the latest MRNS insider to buy. They bought $214,000.00 worth of MRNS shares on Mar 27, 2024.
Dig into more about who owns MRNS stock here.
Can I get consistent income from MRNS stock?
No, Marinus Pharmaceuticals doesn't provide an income stream by paying out dividends.
Get analysis from other investors
One of the reasons eToro is our highest-rated brokerage is because of its social trading community.
Click below to see what other investors have to say.
Step 5: Execute your MRNS trade
There are two primary types of orders:
- Market order: A market order is an order to buy or sell a security at the best possible price.
Market orders are usually fine. - Limit order: A limit order enables you to buy or sell a security at a specific price (or better).
If you want to be certain you're buying or selling at a specific price limit, use a limit order.
Press the Open Trade button and your broker will execute the order.
If you want more help with buying stocks on eToro, click the helpful video below:
Step 6: Keep an eye on your MRNS investment
Now that you own some MRNS stock, you'll want to stay up-to-date on your investment.
Start a watchlist to track the most important metrics related to your MRNS stock.
MRNS Feed
How to Buy Stock in Marinus Pharmaceuticals
To summarize, here are the 6 steps to buy Marinus Pharmaceuticals stock:
- Figure out where to buy Marinus Pharmaceuticals stock
- Sign up for your brokerage account
- Put funds into your brokerage account
- Evaluate Marinus Pharmaceuticals stock
- Execute your MRNS trade
- Keep an eye on your MRNS investment
If you need a online brokerage, eToro is our recommended option.
Get Started with eToro TodayIf you want to get updates on your new investment in Marinus Pharmaceuticals, get started below.
Trending Content
FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterInformation is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.